Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q96AK3

UPID:
ABC3D_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q96AK3; Q5JZ91; Q7Z2N2; Q7Z2N5; Q7Z2N6

BACKGROUND:
DNA dC->dU-editing enzyme APOBEC-3D serves as an essential inhibitor of retrovirus replication, including HIV-1, through its unique DNA deaminase activity. By converting cytosine to uracil in viral DNA, it introduces mutations that are detrimental to the virus's survival. Additionally, it restricts the mobility of various retrotransposons, further showcasing its broad antiviral capabilities. Its action does not extend to double-stranded DNA or RNA, highlighting its specificity.

THERAPEUTIC SIGNIFICANCE:
The exploration of DNA dC->dU-editing enzyme APOBEC-3D's function illuminates promising pathways for drug discovery and development. Its mechanism of inducing mutations in viral DNA could be harnessed to create innovative treatments for retroviral infections, including HIV. The enzyme's specificity and efficiency in targeting viral DNA make it an attractive target for therapeutic intervention.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.